Arrowstreet Capital
ESPR

Arrowstreet Capital’s Esperion Therapeutics ESPR Stock Holding History

Arrowstreet Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,324
Closed -$97K – 1297
2021
Q4 		$97K Buy
+19,324
New +$155K ﹤0.01% 1398
2021
Q1 		– Sell
-136,477
Closed -$3.55M – 2317
2020
Q4 		$3.55M Buy
136,477
+11,415
+9% +$342K 0.01% 1362
2020
Q3 		$4.65M Buy
125,062
+131
+0.1% +$5.19K 0.01% 1175
2020
Q2 		$6.41M Buy
124,931
+86,792
+228% +$3.63M 0.01% 955
2020
Q1 		$1.2M Buy
+38,139
New +$2.01M ﹤0.01% 1248

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital's ESPR Position: Q1 2022 in Review

Arrowstreet Capital sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 19,324 shares — an estimated $97K sold.

Arrowstreet Capital first reported a position in ESPR in Q1 2020 and held it in 5 quarters. The position peaked at $6.41M in Q2 2020. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Arrowstreet Capital reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 19,324 Esperion Therapeutics shares in Q1 2022, an estimated $97K.
  • Arrowstreet Capital first reported a position in Esperion Therapeutics in Q1 2020 and held it in 5 quarters.
  • Arrowstreet Capital's Esperion Therapeutics position peaked at $6.41M in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Arrowstreet Capital's 13F filing for Q1 2022, filed 13 May 2022.